All of our public health officials refuse to answer any of the important questions regarding the mishandling of Lyme disease here in the United States.
---------- Original Message ----------
From: CARL TUTTLE <runagain@comcast.net>
To: Dennis.Dixon1@nih.hhs.gov, tickbornedisease@hhs.gov
Cc: (93 Undisclosed recipients)
Date: March 8, 2020 at 10:27 AM
Subject: Re: March 3-4, 2020, TBDWG Meeting (in-person)
On March 6, 2020 Dennis M. Dixon wrote: “I encourage you to send the information you shared with me to the public comment box at tickbornedisease@hhs.gov to inform the deliberations of the group.”
Dr. Dixon,
You completely avoided my question; “What is your motivation for suppressing evidence of persistent infection after antibiotic treatment?”
An astute fifth grader with access to PubMed can find hundreds of references identifying persistent Borrelia infection after antibiotic treatment but you chose to focus on the 2001 Klempner trials which appear to be our public health justification for the poor response to this runaway plague.
This brings up a few more questions:
1. Does a chronic relapsing seronegative disease fit the vaccine model?
2. Have we been dealing with an antibiotic resistant/tolerant superbug purposely concealed to promote vaccine development as described in my 2018 letter below to Dr. Stanley Plotkin?
PETITION UPDATE
Lemons and Lyme by Stanley Plotkin
https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/23297377
Excerpt:
It is believed that Lyme disease was pigeonholed into its current status by the two principal investigators of the previous Lyme disease vaccines as these investigators conceptualized a disease that would enable vaccine development. (Allen Steere for SmithKlineBeecham's LymeRix and Gary Wormser for Connaught's vaccine which never made it to market)
_____________________________________________
Focusing on the 2001 Klempner trials while ignoring all the other evidence is highly, highly suspicious and suggests high level government involvement in the identified racketeering lawsuit.
We know of a pathogen with similarities to Lyme disease but when persistent symptoms developed after antibiotic treatment, patients were not labeled delusional. Like Lyme disease, there is no test to gauge treatment failure or success.
It was once believed that rifampin was curative in treating Brucellosis but when symptoms returned doxycycline was added to the mix and when that too failed a third antibiotic, streptomycin was added to the current treatment regimen. [1] [2]
In contrast, oral amoxicillin or doxycycline remains the treatment of choice for treating Lyme disease for over thirty years regardless if debilitating symptoms return. Dr. Allen Steere knew in 1977 that these antibiotics were not effective for all patients [3] but there has been no change in treatment or research to find more effective ways to eradicate the infection in all stages of disease. The focus remained on discrediting the sick and disabled so that Lyme could be perceived as “hard to catch and easily treated;” a simple nuisance disease.
Additional question:
3. If Lyme disease is hard to catch and easily treated why do we need a vaccine Dr. Dixon?
Lyme disease belongs in the same health threat category as AIDS, ZIKA and all the other life-altering/life-threatening infections and escalated to Highest Alert for its antibiotic resistant/tolerant properties. But that’s not going to happen as Valneva was granted Fast Track designation by the U.S. Food and Drug Administration for its Lyme vaccine. [4]
For the sake of a vaccine, this well-orchestrated thirty-year con on the public must continue to insure chronic Lyme disease is never recognized while leaving hundreds of thousands (if not millions worldwide) in a debilitated state.
Carl Tuttle
Lyme Endemic Hudson, NH
PS It is no secret that Mark Klempner was named Biowarfare Lab Director for NEIDL and is a Lyme disease Guideline Author. [5]
REFERENCES
[1] Chronic Brucellosis and Persistence of Brucella melitensis DNA
https://www.ncbi.nlm.nih.gov/pubmed/?term=Chronic+Brucellosis+and+Persistence+of+Brucella+melitensis+DNA
After acute brucellosis infection, symptoms persist in a minority of patients for more than 1 year. Such patients are defined as having chronic brucellosis. Since no objective laboratory methods exist to confirm the presence of chronic disease, these patients suffer delays in both diagnosis and treatment.
[2] Administration of a triple versus a standard double antimicrobial regimen for human brucellosis more efficiently eliminates bacterial DNA load.
https://www.ncbi.nlm.nih.gov/pubmed/25246401
The doxycycline-streptomycin-rifampin regimen eliminates Brucella DNA more efficiently than doxycycline-streptomycin, which may result in superior long-term clearance of Brucella.
[3] Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities.
Steere AC, Malawista SE, Snydman DR, Shope RE, Andiman WA, Ross MR, Steele FM.
https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.1780200102
Excerpt:
"The best treatment for this illness is not clear. Some physicians have reported that penicillin or tetracycline results in disappearance of the skin lesion (41,42), but others find antibiotics ineffective. Four of the patients with expanding skin lesions received penicillin but still developed arthritis."
[4] Lyme Disease – VLA15
https://valneva.com/research-development/lyme-disease/
[5] Fear in the Air
by MICHAEL BLANDING· 5/15/2006
https://www.bostonmagazine.com/2006/05/15/fear-in-the-air/
Response from Dr. Denis Dixon from the previous letter posted here: https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/25858157
(There is no “sensitive information” in his email)
--------- Original Message ----------
From: "Dixon, Dennis M. (NIH/NIAID) [E]" <dmdixon@niaid.nih.gov>
To: CARL TUTTLE <runagain@comcast.net>
Cc: "Dixon, Dennis M. (NIH/NIAID) [E]" <dmdixon@niaid.nih.gov>
Date: March 6, 2020 at 6:50 PM
Subject: Re: March 3-4, 2020, TBDWG Meeting (in-person)
Dear Mr. Tuttle,
Thank you for your messages regarding the discussions at the recent public meeting of the Department of Health and Human Services Tick-Borne Diseases Working Group and for taking the time to speak to the entire working group during the public comment period. I encourage you to send the information you shared with me to the public comment box at tickbornedisease@hhs.gov to inform the deliberations of the group.
Dennis M. Dixon, PhD
Chief, Bacteriology and Mycology Branch
Division of Microbiology and Infectious Diseases
HHS/NIH/NIAID
Bethesda, MD 20892
Internet: dd24a@nih.gov
Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.